MedTrace Logo

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

NCT00999466 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-02-26

Study results available
· View outcomes & findings →

Summary

AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.

Conditions

  • Allergic Asthma

Interventions

DRUG

AZD8848

Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.

DRUG

Placebo

Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.

Sponsors & Collaborators

Principal Investigators

  • Leif Eriksson, MD · AstraZeneca R&D Lund

  • Brian Leaker, MD · Respiratory Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-02-28
Completion
2011-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999466 on ClinicalTrials.gov